Fairvalue-Calculator Fairvalue-Calculator
EN DE

Paradigm Biopharmaceuticals Limited (PBIGF) Fair Value & Analysis

Healthcare · US · Market cap $103M

Price$0.1271
Fair Value$0.0400
Upside-68.5%
Quality95/100
Evidence: Low Range $0.0200 – $0.0500

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Paradigm Biopharmaceuticals Limited (PBIGF) currently trades at $0.1271, while our model-based Fair Value estimate is $0.0400 — implying the stock looks roughly 68.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Paradigm Biopharmaceuticals Limited (PBIGF) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.0400 versus a price of $0.1271 — about −69% (overvalued). Model-based estimate, not financial advice.
What is the fair value of PBIGF?
Our 21-model fair value for Paradigm Biopharmaceuticals Limited is $0.0400 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.1271.
What is the quality score of PBIGF?
Paradigm Biopharmaceuticals Limited has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.